Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium.
This study was designed to develop methods for monitoring of the selective factor Xa inhibitor fondaparinux sodium (ARIXTRA) based on standard laboratory methods for the chromogenic determination of the anti-factor Xa activity of low molecular weight heparin. To examine the biologic activity of fondaparinux in comparison to its plasma concentration, 2 methods were investigated: 1 working with the addition of antithrombin (AT), the other without exogenous AT. Both methods showed a linear relationship of fondaparinux concentration and OD/min on a log-lin scale in the range from 0.1 to 2 microg/mL. Inter- and intra-assay variability was <6% in all cases. The results of spiked samples from patients on vitamin K antagonists (VKA) were in good agreement with both methods, and the determination of the fondaparinux concentration was not influenced by reduced levels of factor X in plasma caused by VKA-intake. Ex vivo samples from orthopedic patients (n=18) on prophylactic treatment with fondaparinux showed concentrations between 0.2 to 0.7 microg/mL 3 hours after s.c. injection. No significant differences were detected between both methods with these samples. The presented methods are suitable tools for monitoring of fondaparinux. The linear calibration curve in the range 0.1 to 2 microg/mL is suitable for determination of prophylactic and therapeutic application of fondaparinux. Both methods, with and without addition of AT, can be performed fully automated in clinical routine on an automated coagulation analyzer (STA coagulation analyzer). No significant differences were detected between both methods with these samples.
Klaeffling
C
C
Division of Vascular Medicine, Department of Internal Medicine, J. W. Goethe-University Hospital Frankfurt, Frankfurt/Main, Germany.
Piechottka
G
G
Daemgen-von Brevern
G
G
Mosch
G
G
Mani
H
H
Luxembourg
B
B
Lindhoff-Last
E
E
D000925:Anticoagulants / Q000097:blood*; D000990:Antithrombin III; D002863:Chromogenic Compounds; D016903:Drug Monitoring / Q000379:methods*; D065427:Factor Xa Inhibitors; D005260:Female; D000077425:Fondaparinux; D006801:Humans; D008297:Male; D008875:Middle Aged; D019637:Orthopedic Procedures; D010644:Phenprocoumon / Q000097:blood; D011134:Polysaccharides / Q000097:blood*; D015203:Reproducibility of Results; D014812:Vitamin K / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D002863:Chromogenic Compounds; D065427:Factor Xa Inhibitors; D011134:Polysaccharides; D014812:Vitamin K; D000990:Antithrombin III; D000077425:Fondaparinux; D010644:Phenprocoumon